Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
MEIWA INDUSTRY, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 10%, Oct-Dec Ordinary Profit Decreases by 83%
7284 MEIWA INDUSTRY CO.,LTD. 【J-GAAP】
Earnings ReportMEIWA INDUSTRY CO.,LTD. <7284> [TSE Std] announced its financial results after the market closed on February 12th (15:30). The consolidated ordinary profit for the cumulative third quarter of the fiscal year ending March 2026 (April to December) decreased 10.2% from the same period last year to 185 million yen. Progress toward the full-year plan of 270 million yen was 68.5%, which was higher than the same period of the previous year of 47.4%.
Based on the cumulative third-quarter performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated ordinary profit for the January to March period (4Q) is expected to significant drop 62.9% from the same period last year to 85 million yen.
In the most recent three-month period, from October to December (3Q), the consolidated ordinary profit significantly dropped to 29 million yen, an 82.6% decrease compared to the same period last year. The operating profit margin worsened from 3.1% in the same period last year to 1.0%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Progress Rate vs. First Half | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Apr - Dec, 2023 | 16,827 | -296 | -302 | -412 | -117.9 | ー | Feb 14, 2024 | J-GAAP |
| Apr - Dec, 2024 | 16,899 | 257 | 206 | 65 | 18.8 | 47.4 | Feb 13, 2025 | J-GAAP |
| Apr - Dec, 2025 | 16,996 | 273 | 185 | 127 | 36.5 | 68.5 | Feb 12, 2026 | J-GAAP |
| YoY | +0.6% | +6.2% | -10.2% | +95.4% | +94.7% |
Current Period Guidance
Second Half Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 12,231 | 433 | 396 | 497 | 142.3 | 25 | May 13, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | 12,379 | 213 | 114 | 70 | 20.0 | 25 | Nov 13, 2025 | J-GAAP |
| YoY | +1.2% | -50.8% | -71.2% | -85.9% | -85.9% |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Mar, 2024 | 22,394 | -422 | -448 | -305 | -87.3 | 50 | May 14, 2024 | J-GAAP |
| Mar, 2025 | 23,250 | 505 | 435 | 452 | 129.4 | 50 | May 13, 2025 | J-GAAP |
| Mar, 2026 Guidance | 23,500 | 430 | 270 | 180 | 51.5 | 50 | May 13, 2025 | J-GAAP |
| YoY | +1.1% | -14.9% | -37.9% | -60.2% | -60.2% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 5,880 | 185 | 167 | 110 | 31.8 | 3.1 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 6,351 | 248 | 229 | 387 | 110.8 | 3.9 | May 13, 2025 | J-GAAP |
| Apr - Jun, 2025 | 5,531 | 44 | 40 | 12 | 3.6 | 0.8 | Aug 6, 2025 | J-GAAP |
| Jul - Sep, 2025 | 5,590 | 173 | 116 | 98 | 28.0 | 3.1 | Nov 13, 2025 | J-GAAP |
| Oct - Dec, 2025 | 5,875 | 56 | 29 | 17 | 4.9 | 1.0 | Feb 12, 2026 | J-GAAP |
| YoY | -0.1% | -69.7% | -82.6% | -84.5% | -84.6% |
Related Articles
ROHTO PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 6%, Exceeded Record Profit Forecast, Dividend Revised Upward by 1 Yen
CRI Middleware, Oct-Dec (1Q) Ordinary Profit Decreases by 74%
ExaWizards, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Profit, Oct-Dec Ordinary Profit Increases by 237 times
Human Metabolome Tech, First Half Ordinary Profit Decreases by 50%
NETSTARS, 60% Increase in Ordinary Profit, Update Record High for Second Consecutive Term
Relo Group, Apr-Dec (Cumulative 3Q) Net Income Decreases by 61%
PIOLAX, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 25%
TBK, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 30%
Shikino High-Tech, Ordinary Profit Forecast for the Fiscal Year Revised Downward to a Loss
StemCell Institute, Apr-Dec (Cumulative 3Q) Ordinary Profit Decreases by 38%, Oct-Dec Ordinary Profit Decreases by 11%